Human Antibodies and Hybridomas 1993: Vol 4 Index

3 Pages·1993·1.1 MB·English

Author Index
AshSbByun, J.M.: ° SSeaee Li;, Y.P , eott a< l., 27 6 Eremin, O.: See Li, Y., et al.. 26 methods of isolating amplified cDNA
Atkin, J.D.: See Bender, E., et al., 74 affects cloning efficiency, 104
Feng, O.: See Liu, H., et al., 2 Leslie, G.: See Ditzel, H., et al., 86
Baba, M., Kobayashi, T., Oka, Y., Yagyu, Ferraro, A.S., Newkirk, M.M.: In vitro Li, Y.: See Liu, H., et al., 2
r., Tamaki, Y., Takeda, T., Monden, T stimulation of human peripheral blood B Li, Y., Ashby, J.M., Eremin, O.: In vitro
Shimano, T., Tsuji, Y.. Murakami, H cells from normal individuals by activated primary immunization of B lymphocytes
Preparation of a human monoclonal I cells increases the efficiency of for producing human monoclonal
antibody derived from cervical lymph hybridoma generation, 80 antibodies against tumor-associated
nodes of a patient with anaplastic Fujimoto, S.: See Bitoh, S., et al., 134 antigens, 26-30
carcinoma of the thyroid, 181 Aindhout, E.: See Mevissen, M.L.C.M., et
Barker, M.D.: See Bender, E., et al., 74 Glassy, M.C.: Production methods for al., 66
Bebbington, C.R.: See Bender, E., et al., generating human monoclonal antibodies, iu, H., Xu, Z.-L., Wang, Y., Yang, L.,
74 154 Feng, O., Li, Y., Wang, Y.-M., Zhang,
Bell, D.A.: See Denomme, G.A.., et al., 98 Gonzalez, M.F.: See Sanchez, B., et al., 198 G.-G.: Production of anti-tumor human
Bende, R.J.: See Jochems, G.J., et al., 124 Goodall, M.: See Lund, J., et al., 20 monoclonal antibodies using different
Bender, E., Woof, J.M., Atkin, J.D., Goormachtig, E.: See Mevissen, M.L.C.M., approaches, 2-8
Barker, M.D., Bebbington, C.R., Burton, et al., 66 Liu, T.: See Meredith, R.F , et al., 190
D.R.: Recombinant human antibodies Grizzle, W.E See Meredith, R.F., et al., Liu, X.: See Zhu, Y , et al., 31
linkage of an Fab fragment from a 190 LoBuglio, A.F See Cartner, A.M., et al.,
combinational library to an Fc fragment for 174
expression in mammalian cell culture, 74 Haenftling, K.: See Daifuku, R , et al., 36 LoBuglio, A.F See Meredith, R.F., et al.,
Bitoh, S., Lang, G.M., Sehon, A.H 174
Hagiwara, H., Yuasa, H.: Generation of
Suppression of human anti-mouse somatic cell hybrids capable of und, J., Takahashi, N., Hindley, S., Tyler,
idiotypic antibody responses in hu-PBL- proliferating and secreting human R., Goodall, M., Jefferis, R
SCID mice, 144 monoclonal antibody without any growth Glycosylation of human IgG subclass and
Bitoh, S., Lang, G.M., Kierek-Jaszczuk, D., factor supplements, 15 mouse IgG2b heavy chains secreted by
Fujimoto, S., Sehon, A.H.: Specific Hashizume, S.: See Kato, M., et al., 9 mouse J558L transfectoma cell lines as
immunosuppression of human anti-murine Hashizume, S.: See Yasumoto, K , et al., chimeric antibodies, 20
antibody (HAMA) responses in hu-PBL-
SCID mice, 134 Hin1d8l6e y, S.: See Lund, J , et al., 20 Mahmoudi, M.: See Denomme, G.A.., et al.,
Boerner, P.: See Brams, P., et al., 47, 57 Huang, C.: See Zhu, Y , et al., 31 OS
Borrebaeck, C.A.K.: See Ifversen, P., et al., Massicotte, H See Denomme, G.A.., et al.,
115 Ifversen, P., Xiu-Mei, Z., Ohlin, M., OS
Brams, P., Royston, |., Boerner, P.: In vitro Melero, J.: See Sanchez, B., et al., 198
Zeuthen, J., Borrebaeck, C.A.K.: Effect
priming of human lymphocytes. I. IL-2 and Meredith, R.F., Khazaeli, M.B., Grizzle,
of cell derived growth factors and cytokines
IL-4 requirements, 47 W.E., Orr, R.A., Plott, G., Urist, M.M.,
on the clonal outgrowth of EBV infected-
Brams, P., Royston, I., Boerner, P In vitro Liu, T., Russell, C.D., Wheeler, R.H.,
B cells and established lymphoblastoid cell
priming of human lymphocytes. II Schlom, J., LoBuglio, A.F.: Direct
lines (LCL), 115
Induction of antigen-specific IgG responses localization comparison of murine and
by repeated antigen stimulation, 57 chimeric B72.3 antibodies in patients with
Burton, D.R.: See Bender, E., et al., 74 Jefferis, R.: See Lund, J., et al., 20 colon cancer, 190
Jensenius, J.C.: See Ditzel, H., et al., 86 Mevissen, M.L.C.M., Kwekkeboom, J.,
Cairns, E.: See Denomme, G.A.., et al., 98 Jin, B.: See Zhu, Y., et al., 31 Goormachtig, E., Lindhout, E., de Groot,
Cartner, A.M., Conry, R.M., Safavy, A., Jochems, G.J., Bende, R.J., Klein, M.R.., C.: Improvement of EBV transformation
Khazaeli, M.B., Sumerel, L.A.., Zeijlemaker, W.P., van Lier, R.A.W and cloning efficiency of human B cells
Expression of the II-6 gene induces
LoBuglio, A.F.: An animal model to using culture supernatants from
predict the immunogenicity of murine V- differentiation of a human monoclonal lymphoblastoid cell lines, 66
regions in humans, 174 EBV transformed cell line, 124 Mochizuki, K.: See Kato, M., et al., 9
Conry, R.M.: See Cartner, A.M., et al., 174 Johnson, J.L.: See Daifuku, R., et al., 36 Monden, T.: See Baba, M., et al., 181
Mori, T.: See Baba, M., et al., 181
Daifuku, R., Panacek, E.A., Haenftling, K., Kamei, M.: See Yasumoto, K., et al., 186 Murakami, H.: See Kato, M., et al., 9
Swenson, W.K., Prescott, A.W., Johnson, Kato, M.: See Yasumoto, K., et al., 186 Murakami, H.: See Tachibana, H., et al., 42
J.L.: Pilot study of anti-lipopolysaccharide Kato, M., Mochizuki, K., Hashizume, S.. Murakami, H.: See Yasumoto, K., et al.,
human monoclonal antibody MAB-TS88 in Tachibana, H., Shirahata, S., Murakami, 186
patients with gram-negative sepsis, 36 H.: Activity enhancement of a lung cancer- Murakami, See Baba, M., et al., 181
Dang, H.: See Lazaridis, K., et al., 104 associated human monoclonal antibody
de Groot, C.: See Mevissen, M.C.L.M.., et HB4C5 by N-deglycosylation, 9 Newkirk, M.M.: See Ferraro, A.S., 80
al., 66 Khazaeli, M.B.: See Cartner, A.M a, ; = Newkirk, M.M.: See Rioux, J.D., et al., 107
Denomme, G.A., Mahmoudi, M., Edwards, 174 Nomoto, K.: See Yasumoto, K., et al., 186
J.Y., Massicotte, H., Cairns, E., Bell, Khazaeli, M.B See Meredith, R.F , et al.,
D.A.: Immunoglobulin V region heavy and 190 Ohlin, M.: See Ifversen, P., et al., 115
light chain gene sequences of the Kierek-Jaszczuk, D See Bitoh, S., et al., Oka, Y.: See Baba, M., et al., 181
lymphoblastoid cell line GM 4672, 98 134 Orr, R.A.: See Meredith, R.F., et al., 190
Ditzel, H., Erb, K., Leslie, G., Jensenius, Klein, M.R.: See Jochems, G.J., et al., 124
J.C.: Preparation of antigen-binding Kobayashi, Tetsuro: See Baba, M , et al., Panacek, E.A.: See Daifuku, R , et al., 36
monomeric and half-monomeric fragments 181 Plott, G.: See Meredith, R.F , et al., 190
from human monoclonal IgM antibodies Kwekkeboom, J See Mevissen, M.L.C.M.., Prescott, A.W See Daifuku, R., et al., 36
against colorectal cancer-associated et al., 66
antigens, 86 Rauch, J.: See Rioux, J.D., et al., 107
Lang, Glen M.: See Bitoh, S., et al., 144 Rioux, J D., Rauch, J., Zdarsky, E.,
edwards, J.Y.: See Denomme, G.A.., et al., Lang, Glen M.: See Bitoh, S., et al., 134 Newkirk, M.M.: Molecular
98 Lazaridis, K., Dang, H., Talal, N.: Human characterization of the GM 4672 human
Erb, K.: See Ditzel, H., et al., 86 K chain expression in a phage vector lymphoblastoid cell line and analysis of its
use as a fusion partner in the generation Sun, C.: See Zhu, Y., et al., 31 Wheeler, R.H.: See Meredith, R.F., et al.,
of human-human hybridoma Swenson, W.K.: See Daifuku, R., et al., 36 190
autoantibodies, 107 Woof, J.M.: See Bender, E., et al., 74
RRooybsiteodno,, MI..: MS.e:e SBerea mSsa,n chPe.z, , et B.,a l.,e t 47al,., 571 98 TTaacchhiibbaannaa,, HH..:, SSehei raKhaattoa,, MS..,, Metu raal.k,a m9 i, Xiu-Mei, Z.: See Ifversen, P., et al., 115
Russell, C.D.: See Meredith, R.F., et al., H.: Human bifunctional antibody Xu, Z.-L.: See Liu, H., et al., 2
190 generated by heterologous association of Yagyu, Toshio: See Baba, M.., et al., 181
heavy and light chains, 42 Yang, L.: See Liu, H., et al., 2
Safavy, A.: See Cartner, A.M., et al., 174 Takahashi, N.: See Lund, J., et al., 20 Yasumoto, K., Setoguchi, Y., Kamei, M.,
Sanchez, B., Melero, J., Robledo, M.M., Takeda, T.: See Baba, M., et al., 181 Kato, M., Nomoto, K., Murakami, H.,
Tarrago, D., Yelamos, J., Gonzalez, M.F Talal, N.: See Lazaridis, K., et al., 104 Hashizume, S.: Cancer-specific binding of
Application of cellular Elisa (CELISA) to Tamaki, Y.: See Baba, M., et al., 181 a mouse MoAb vs. Candida krusei
the detection of human monoclonal Tarrago, D.: See Sanchez, B., et al., 198 cytochrome c: an antigen recognized by a
autoantibodies, 198 The, T.H.: See Steenbakkers, P.G.A., et cancer-associated human MoAb HB4CS,
Schlom, J.: See Meredith, R.F., et al., 190 al., 166 186
Sehon, A.H.: See Bitoh, S., et al., 134 Tsuji, Y.: See Baba, M., et al., 181 Yelamos, J.: See Sanchez, B., et al., 198
Sehon, A.H.: See Bitoh, S., et al., 144 Tyler, R.: See Lund, J., et al., 20 Yuasa, and Yuasa, H.: See Hagiwara, H..,
Setoguchi, Y.: See Yasumoto, K., et al., 186 15
Shimano, T.: See Baba, M.., et al., 181
Urist, M.M.: See Meredith, R.F., et al., 190
Shirahata, S.: See Kato, M., et al., 9 Zdarsky, E.: See Rioux, J.D., et al., 107
Shirahata, S.: See Tachibana, H., et al., 42 Zeijlemaker, W.P.: See Jochems, G.J., et
Steenbakkers, P.G.A., Van Wezenbeck, van Lier, R.A.W.: See Jochems, G.J., et al., al., 124
P.M.G.F., van Zanten, J., The, T.H.: 124 Zeuthen, J.: See Ifversen, P., et al., 115
Efficient generation of human anti- Van Wezenbeck, P.M.G.F.: See Zhang, G.-G.: See Liu, H., et al., 2
cytomegalovirus IgG monoclonal Steenbakkers, P.G.A., et al., 166 Zhu, Y., Jin, B., Sun, C., Huang, C., Liu,
antibodies from preselected antigen- van Zanten, J.: See Steenbakkers, et al., 166 X.: The effects of hybridoma growth factor
specific B cells, 166 in conditioned media upon the growth,
Sumerel, L.A.: See Cartner, A.M , et al., Wang, Y.: See Liu, H., et al., 2 cloning, and antibody production of
174 Wang, Y.-M.: See Liu, H., et al., heterohybridoma cell lines, 31
Subject Index
Activation, 9 Gram-negative, 36 Lipopolysaccharide, 36
Anaplastic carcinoma, 181 Local Immunotherapy, 181
Antibody, 66, 174, 190 Half-monomeric, 86 Localization, 190
Antibody secretion, 31 HAMA, 134, 144 Lung cancer, 186
Anti-CD3 activated T cells, 80 Heterogeneity, 9 Lymphokine requirements, 47
Anti-idiotype, 144 Heterohybridoma, 31
Anti-tumor monoclonal antibody, 2 Heterologous association, 42 Mini-electrofusion, 166
Antigen-binding, 86 Human autoantibodies, 107 Monoclonal antibodies, 107, 174
Antigen binding site, 9 Human antibody, 74 Monoclonal antibody, 36, 181
Antigen-specific B cells, 166 Human B cells, 66 Monoclonal antibody HB4CS, 9
Autoantibody, 198 Human < human < human x hybridoma, Monomeric, 86
Autocytotoxicity, 198 15 MP6, 115
Human-human hybridoma, 2, 181 mPEG conjugate, 134
Bifunctional antibody, 42 Human hybridoma, 107
Breast cancer, 26 Human lymphocytes, 47 N-glycosylation, 9
Human monoclonal antibodies, 80 No keywords, 124
Cancer-associated antigen, 186 Human monoclonal antibody, 2, 15, 26, 42,
Candida krusei cytochrome c, 186 86, 166, 198 Polymerase chain reaction, 104
Cell hybridization, 107 Human monoclonal antibody HB4CS5, 186 Polyreactivity, 198
Chimera, 190 Human-mouse hybridoma, 2
Chimeric IgG, 20 Human spleen cells, 57 Quantitation, 190
CHO cells, 74 hu-PBL-SCID mice, 134
Cloning, 31 Hybridoma growth factor, 31 Rabbit, 174
CMV B cell clone, 166 Radiolabel, 190
Colorectal cancer, 86 IgG responses, 57 Recombinant antibody, 104
Conditioned media, 31 IgM, 36 Restimulation, 57
Cytokines, 66 IL-2, 47
IL-4, 47 SCID mice, 144
DNA isolation, 104 Immune response, 174 Selection, 166
Immunoglobulin repertoire cloning, 74 Sepsis, 36
EBV-infection, 115 Immunoglobulin sequence, 107 Serum-free medium, 15
EBV hybridoma, 2 Immunohistochemistry, 181
ELISA, 198 Immunostaining, 186 Tetanus toxoid, 74
Epstein-Barr virus transformation, 66 Immunosuppression, 144 Thioredoxin, 115
In vitro immunization, 26, 47 Thyroid cancer, 181
Fragment, 86 In vitro priming, 57 Tolerance, 134, 144
Fusion partner, 107 Trioma, 15
Light chain, 42 Tumor-associated antigen, 26
Glycosylation control, 20 Light chain, 9 Tumor cell antigen, 15